Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Chemotherapy in Newly Diagnosed ALL
NCT05386576Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in acute lymphoblastic leukemia (ALL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose Limiting Toxicities at 6 weeks. Started Jun 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05386576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386576.